Mark A. Eckardt

PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.

Joshua E. Logan, Nikayeh Mostofizadeh, Amrita Desai et al. · PubMed · 2013 · 102 citations

Effective molecular targeting of CDK4/6 and IGF-1R in a rare <i>FUS-ERG</i> fusion <i>CDKN2A</i>-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model

Takashi Murakami, Arun S. Singh, Tasuku Kiyuna et al. · Oncotarget · 2016 · 97 citations · Full text

Pathology, Effective Molecular Targeting, Cancer Biology +20

Tumor-targeting Salmonella typhimurium A1-R combined with recombinant methioninase and cisplatinum eradicates an osteosarcoma cisplatinum-resistant lung metastasis in a patient-derived orthotopic xenograft (PDOX) mouse model: decoy, trap and kill chemotherapy moves toward the clinic

Kentaro Igarashi, Kei Kawaguchi, Tasuku Kiyuna et al. · Cell Cycle · 2018 · 72 citations · Full text

Recombinant methioninase in combination with doxorubicin (DOX) overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of undifferentiated spindle-cell sarcoma

Kentaro Igarashi, Kei Kawaguchi, Shukuan Li et al. · Cancer Letters · 2018 · 66 citations

Tumor Biology, Cancer Cell Biology, First-line Dox Resistance +6

Targeting methionine with oral recombinant methioninase (o-rMETase) arrests a patient-derived orthotopic xenograft (PDOX) model of BRAF-V600E mutant melanoma: implications for chronic clinical cancer therapy and prevention

Kei Kawaguchi, Qinghong Han, Shukuan Li et al. · Cell Cycle · 2017 · 59 citations · Full text

Chemoprevention Strategy, Braf-v600e Mutant Melanoma, Tumor Biology +19